01/2021 journal articles
PSYCHOLOGICAL DISORDERS, COGNITIVE IMPAIRMENT, AND QUALITY OF LIFE WITH CHEMOTHERAPY-INDUCED NEUROPATHY IN COLON AND RECTAL CARCINOMA
Li Hongyan, Lu Wanting, Li Fei
Care Weekly 2021;5:1-6Show summaryHide summary
Purpose: To evaluate mental health, cognitive function, and living quality of colon and rectal carcinoma patients with oxaliplatin-induced neurotoxicity.
Methods: Fifty recurrence-free colorectal cancer (CRC) patients with oxaliplatin chemotherapy while 50 control patients without oxaliplatin chemotherapy were enrolled in this study. Subjective and objective aspects of oxaliplatin chemotherapy symptoms were assessed with oxaliplatin neurotoxicity classification. Psychological assessment was measured via the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). Cognitive function was measured via Montreal Cognitive Assessment (MoCA). Quality of Life (QOL) was assessed using the World Health Organization’s Quality of Life (WHOQOL-BREF) shortened instrument.
Results: Of the patients with oxaliplatin chemotherapy, 41 patients had depression and 42 patients had anxiety. Patients with oxaliplatin chemotherapy scored higher on average on both the SDS (64.36 ± 7.22) and SAS (67.49 ± 9.41) compared to those without oxaliplatin chemotherapy (SDS, 57.86 ± 5.27, p=0.006; SAS, 61.57 ± 10.06, p = 0.004). Patients with oxaliplatin chemotherapy, on average, scored lower on the MoCA (23.46 ± 3.17) compared to patients without oxaliplatin chemotherapy (27.49 ± 2.03, p < 0.05). In addition, patients with oxaliplatin chemotherapy scored significantly lower on measures of physical health (18.9 ± 7.8 vs. 37.8 ± 6.2, p<0.05), psychological health (19.3 ± 8.2vs. 39.8 ± 8.1, p<0.05), and social relationship (50.2 ± 10.1 vs. 70.6 ± 10.5, p<0.05) compared to patients without oxaliplatin chemotherapy. Multivariate linear regression analysis demonstrated that anxiety and cognitive impairment performance significantly predicted for global Quality of Life (QOL).
Conclusions: colorectal cancer (CRC)patients with oxaliplatin chemotherapy experience mood disorders, cognitive impairment, and reduced Quality of Life (QOL). The clinical symptoms severity of oxaliplatin cemotherapy plays an important role in mood change and cognitive function. Decreased Quality of Life (QOL) was associated with anxiety and cognitive impairment.
Li Hongyan ; Lu Wanting ; Li Fei (2021): Psychological Disorders, Cognitive Impairment, and Quality of Life with Chemotherapy-induced Neuropathy in Colon and Rectal Carcinoma Patients. Care Weekly. http://dx.doi.org/10.14283/cw.2021.1
MECOBALAMIN AS A NEUROPROTECTIVE EFFECTOR AGAINST OXALIPLATIN-BASED CHEMOTHERAPY IN COLON AND RECTAL CANCER PATIENTS
Li Hongyan, Lu Wanting, Li Fei
Care Weekly 2021;5:7-11Show summaryHide summary
Palliative chemotherapy prolongs survival and improves quality of life. However, a variety of chemotherapeutics including oxaliplatin can cause severe side effects during treatments, leading to painful symptoms that might result in the interruption of cancer treatment. Although adding oxaliplatin to fluorouracil and leucovorin in adjuvant chemotherapy for colon and rectal cancer may improve disease-free survival, it also increases grade 3–4 sensory neuropathy. Our study aimed to determine whether oral Mecobalamin is neuroprotective against oxaliplatin-induced neuropathy. Forty-six stage III colon and rectal cancer patients receiving adjuvant biweekly oxaliplatin were randomized to oral Mecobalamin (1,500 mg; case group) or placebo (control group). Clinical neurological and electrophysiological evaluations were performed at baseline and after 4, 8, and 12 treatment cycles. Treatment-related toxicity was evaluated based on National Cancer Institute (NCI) criteria. After four cycles of chemotherapy, 9 of 23 patients in the control group and 8 of 23 patients in case group experienced grade 1 sensory neuropathy. After eight cycles, 13 patients experienced sensory neuropathy (grade 2–4 toxicity) in the control group; however, no patients in the case group experienced sensory neuropathy (P < 0.05). After 12 cycles, grade 2–4 sensory neuropathy was observed in 20 patients in the control group, but only in 4 patients in the case group (P < 0.05). We did not observe any significant electrophysiological changes in the case group after 4, 8, or 12 cycles of chemotherapy. Thus, we demonstrated that oral Mecobalamin reduces the incidence of neuropathy in colon and rectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li Hongyan ; Lu Wanting ; Li Fei (2021): Mecobalamin as a Neuroprotective Effector against Oxaliplatin-Based Chemotherapy in Colon and Rectal Cancer Patients. Care Weekly. http://dx.doi.org/10.14283/cw.2021.2
UNIVERSAL DESIGN AS A PARADIGM FOR PROVIDING HEALTH INTERVENTIONS FOR OLDER ADULTS 1
Peter J. Snyder
Care Weekly 2021;5:12-16Show summaryHide summary
Peter J. Snyder (2021): Universal Design as a Paradigm for Providing Health Interventions for Older Adults 1. Care Weekly. http://dx.doi.org/10.14283/cw.2021.3